Incb106385 (Not yet branded)
Other Medications
Description
INCB106385 is an oral small molecule compound developed by Incyte Corporation for treatment of advanced solid tumors including colorectal cancer. This agent represents a novel therapeutic approach targeting specific cellular pathways involved in tumor growth and survival. Based on early-phase clinical trial data, it shows activity as both monotherapy and in combination with immunotherapy agents for patients with metastatic or locally advanced colorectal cancer.
Mechanism of Action
INCB106385 functions as a selective inhibitor of specific kinase pathways that regulate tumor cell proliferation and survival, though the exact molecular target has not been fully disclosed in public databases. The compound appears to modulate intracellular signaling cascades that are frequently dysregulated in colorectal cancer, potentially affecting both tumor growth and the immune microenvironment.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.